<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00091286</url>
  </required_header>
  <id_info>
    <org_study_id>9976</org_study_id>
    <secondary_id>UVACC-GI37</secondary_id>
    <secondary_id>UVACC-23302</secondary_id>
    <nct_id>NCT00091286</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Stage IIB, Stage III, or Stage IV Colorectal Cancer</brief_title>
  <official_title>Evaluation of the Immunogenicity of Vaccination With HER-2/Neu and CEA Derived Synthetic Peptides With GM-CSF-in-Adjuvant, in Patients With Stage IIB, III, or IV Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Craig L Slingluff, Jr</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from peptides may make the body build an immune response to kill&#xD;
      tumor cells.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying how well vaccine therapy works in treating patients&#xD;
      with stage IIB, stage III, or stage IV colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine whether vaccination comprising HER-2-neu and carcinoembryonic antigen&#xD;
           synthetic peptides, sargramostim (GM-CSF), and Montanide ISA-51 causes an immune&#xD;
           response in patients with stage IIB, III, or IV colorectal cancer.&#xD;
&#xD;
        -  Determine the safety of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: Patients receive vaccination comprising HER-2-neu and carcinoembryonic antigen&#xD;
      synthetic peptides, sargramostim (GM-CSF), and Montanide ISA-51 on days 1, 8, and 15. On day&#xD;
      22, patients undergo removal of the lymph node into which the vaccination site drains to&#xD;
      determine whether the immune system is responding to the vaccine.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 15 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow accruals&#xD;
  </why_stopped>
  <start_date type="Actual">March 24, 2003</start_date>
  <completion_date type="Actual">February 15, 2008</completion_date>
  <primary_completion_date type="Actual">February 15, 2008</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of the 4-peptide mixture</measure>
    <time_frame>30 days following last vaccine</time_frame>
    <description>Adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with an immune response to the peptides</measure>
    <time_frame>through Day 22</time_frame>
    <description>T cell responses against the peptides as measured in the sentinel immunized node</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of the peptide mixture measured in the peripheral blood</measure>
    <time_frame>through Day 22</time_frame>
    <description>T cell responses against the peptides and/or tumor</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Peptide Vaccine + Montanide + GM-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Colon peptide mixture (100 mcg each of the 4 peptides) plus 190 mcg of tetanus toxoid peptide, plus GM-CSF (110 mcg) in Montanide ISA-51 adjuvant</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HER-2-neu, CEA peptides, GM-CSF, Montanide ISA-51 vaccine</intervention_name>
    <arm_group_label>Peptide Vaccine + Montanide + GM-CSF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of colorectal cancer&#xD;
&#xD;
               -  Stage IIB, III, or IV disease&#xD;
&#xD;
          -  HLA-A2- or -A3-positive&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,000/mm^3&#xD;
&#xD;
          -  Hemoglobin &gt; 9 g/dL&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Liver function tests ≤ 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No known or suspected allergies to any component of the study drug&#xD;
&#xD;
          -  No active connective tissue disease requiring medications&#xD;
&#xD;
          -  No systemic autoimmune disease with visceral involvement&#xD;
&#xD;
          -  No uncontrolled diabetes&#xD;
&#xD;
          -  No other severe autoimmune disease&#xD;
&#xD;
          -  No medical contraindication or potential problem that would preclude study compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  More than 30 days since prior immunotherapy&#xD;
&#xD;
          -  More than 30 days since prior growth factors&#xD;
&#xD;
          -  More than 30 days since prior allergy shots&#xD;
&#xD;
          -  No prior vaccination with any study peptides for malignancy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 30 days since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  More than 30 days since prior steroids&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 30 days since prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  More than 30 days since prior surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 30 days, but ≤ 24 months, since prior therapy for colorectal cancer&#xD;
&#xD;
          -  No concurrent illegal drug use&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles M. Friel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Virginia Cancer Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 7, 2004</study_first_submitted>
  <study_first_submitted_qc>September 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2004</study_first_posted>
  <last_update_submitted>March 26, 2020</last_update_submitted>
  <last_update_submitted_qc>March 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Craig L Slingluff, Jr</investigator_full_name>
    <investigator_title>Director, Human Immune Therapy Center</investigator_title>
  </responsible_party>
  <keyword>recurrent colon cancer</keyword>
  <keyword>stage IIB colon cancer</keyword>
  <keyword>stage IIIA colon cancer</keyword>
  <keyword>stage IIIB colon cancer</keyword>
  <keyword>stage IIIC colon cancer</keyword>
  <keyword>stage IVA colon cancer</keyword>
  <keyword>stage IVB colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>stage IIB rectal cancer</keyword>
  <keyword>stage IIIA rectal cancer</keyword>
  <keyword>stage IIIB rectal cancer</keyword>
  <keyword>stage IIIC rectal cancer</keyword>
  <keyword>stage IVA rectal cancer</keyword>
  <keyword>stage IVB rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

